Inflammation playing a key role in heart evaluations | Contrast in the cath lab | PE-backed cardiology group makes a deal

From new drug therapies and imaging technologies to updated prevention strategies, nearly every aspect of cardiovascular care is starting to embrace the value of coronary inflammation evaluations. Paul Ridker, MD, MPH, discussed the trend in a new interview.

Researchers emphasized that minimizing procedural contrast use is an effective way to reduce the risk of post-PCI acute kidney injury. 

Medical students pointed to a lack of experience with cardiothoracic surgery as a primary reason for their lack of interest. In addition, many believe they may encounter a bias against Black trainees if they got involved in the specialty.

Cardiovascular Associates of America and cardiologist-founded HybridChart are now working together in a move designed to deliver value-based care to heart patients.

Newsweek and Statista have crunched the data and ranked the top U.S. hospitals for cardiac care. Did your facility make the cut? 

Using a standardized approach, including the cusp overlap technique, is associated with improved patient outcomes when implanting Medtronic's self-expanding TAVR valves. Researchers tracked data from more than 600 patients treated all over the world, presenting their findings in JSCAI.

Rishi Wadhera, MD, detailed new data that show how socioeconomic factors are driving cardiovascular death rates, especially in younger adults.

“Rather than condemning all added sugars, future dietary guidelines might consider the differential effects of sugar based on its source and form," one researcher said.

The company told Cardiovascular Business it respectfully disagrees with the jury's decision and is evaluating all possible legal options going forward. The Association of Medical Device Reprocessors, meanwhile, celebrated the news.

When low-risk patients undergo transfemoral TAVR, they may be able to go home without spending a single night at the hospital.

Researchers tracked data from nearly 400 women with complex CAD who underwent treatment with Shockwave Medical's intravascular lithotripsy technology prior to PCI.

Returning CEO Stephen Hemsley will receive a base salary of $1 million per year, alongside a one-time bonus package in stocks worth $60 million. He is not eligible to receive future bonuses until 2028, the company confirmed in a SEC filing. 

This task could potentially be performed by a member of the radiology scheduling team with oversight by a clinical nurse navigator.